PRODUCT INFORMATION

Solcitinib
Item No. 23439

CAS Registry No.: 1206163-45-2
Formal Name: N-[5-[4-[[3,3-dimethyl-1-azetidinyl] carbonyl]phenyl][1,2,4]triazolo[1,5-a] pyridin-2-yl]-cyclopropanecarboxamide
Synonyms: GLPG0778, GSK2586184
MF: C_{22}H_{23}N_{5}O_{2}
FW: 389.5
Purity: ≥ 98%
UV/Vis.: λ_{max} = 201, 231, 303 nm
Supplied as: A crystalline solid
Storage: -20°C
Stability: ≥ 2 years

Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

Solcitinib is supplied as a crystalline solid. A stock solution may be made by dissolving the solcitinib in the solvent of choice. Solcitinib is soluble in organic solvents such as ethanol, DMSO, and dimethyl formamide, which should be purged with an inert gas. The solubility of solcitinib in these solvents is approximately 1, 5, and 2 mg/ml, respectively.

Description

Solcitinib is an inhibitor of JAK1 (IC_{50} = <100 and >100 nM for JAK1 and JAK2, respectively).\textsuperscript{1} Formulations containing solcitinib have been evaluated in clinical trials for the treatment of moderate-to-severe psoriasis, ulcerative colitis, and systemic lupus erythematosus (SLE).\textsuperscript{2} However, clinical trials using formulations containing solcitinib for the treatment of SLE were terminated early due to elevated liver enzymes and at least one case of drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome.\textsuperscript{3}

References